A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy

EARLY_PHASE1Enrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 16, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2027

Conditions

Immunoglobulin A Nephropathy (IgAN)

Interventions

DRUG

Biological: cizutamig

Cizutamig will be dosed according to the protocol.

Trial Locations (1)

Peking University First Hospital, Beijing

All Listed Sponsors

lead

Peking University First Hospital

OTHER